Abstract
Testicular responsiveness to 5,000 IU of human chorionic gonadotropin was evaluated in 14 patients with prostate cancer who were being treated with a slow-releasing luteinizing hormone-releasing hormone agonist for a median of 21 months. Serum testosterone response to human chorionic gonadotropin was markedly reduced in most patients, with the median level increasing from 0.25 to 1.65 nmol per l. A second human chorionic gonadotropin test was repeated later in 5 patients who had been off treatment for a median of 6 months. Median serum testosterone levels increased to a maximum of 2.6 nmol per l compared to 28.2 nmol per l in an age-matched control group (p equals 0.008). Therefore, we conclude that long-term treatment with luteinizing hormone-releasing hormone agonists in elderly men leads to gonadal impairment that may not be as reversible as generally suggested.
| Original language | English |
|---|---|
| Pages (from-to) | 1235-2138 |
| Number of pages | 904 |
| Journal | Journal of Urology |
| Volume | 142 |
| Issue number | 5 |
| Publication status | Published - 1989 |
Fingerprint
ASJC Scopus subject areas
- Urology
Cite this
Evidence for testicular impairment after long-term treatment with a luteinizing hormone-releasing hormone agonist in elderly men. / Decensi, A. U.; Guarneri, D.; Marroni, P.; Di Cristina, L.; Paganuzzi, M.; Boccardo, F.
In: Journal of Urology, Vol. 142, No. 5, 1989, p. 1235-2138.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Evidence for testicular impairment after long-term treatment with a luteinizing hormone-releasing hormone agonist in elderly men
AU - Decensi, A. U.
AU - Guarneri, D.
AU - Marroni, P.
AU - Di Cristina, L.
AU - Paganuzzi, M.
AU - Boccardo, F.
PY - 1989
Y1 - 1989
N2 - Testicular responsiveness to 5,000 IU of human chorionic gonadotropin was evaluated in 14 patients with prostate cancer who were being treated with a slow-releasing luteinizing hormone-releasing hormone agonist for a median of 21 months. Serum testosterone response to human chorionic gonadotropin was markedly reduced in most patients, with the median level increasing from 0.25 to 1.65 nmol per l. A second human chorionic gonadotropin test was repeated later in 5 patients who had been off treatment for a median of 6 months. Median serum testosterone levels increased to a maximum of 2.6 nmol per l compared to 28.2 nmol per l in an age-matched control group (p equals 0.008). Therefore, we conclude that long-term treatment with luteinizing hormone-releasing hormone agonists in elderly men leads to gonadal impairment that may not be as reversible as generally suggested.
AB - Testicular responsiveness to 5,000 IU of human chorionic gonadotropin was evaluated in 14 patients with prostate cancer who were being treated with a slow-releasing luteinizing hormone-releasing hormone agonist for a median of 21 months. Serum testosterone response to human chorionic gonadotropin was markedly reduced in most patients, with the median level increasing from 0.25 to 1.65 nmol per l. A second human chorionic gonadotropin test was repeated later in 5 patients who had been off treatment for a median of 6 months. Median serum testosterone levels increased to a maximum of 2.6 nmol per l compared to 28.2 nmol per l in an age-matched control group (p equals 0.008). Therefore, we conclude that long-term treatment with luteinizing hormone-releasing hormone agonists in elderly men leads to gonadal impairment that may not be as reversible as generally suggested.
UR - http://www.scopus.com/inward/record.url?scp=0024442019&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024442019&partnerID=8YFLogxK
M3 - Article
C2 - 2530360
AN - SCOPUS:0024442019
VL - 142
SP - 1235
EP - 2138
JO - Journal of Urology
JF - Journal of Urology
SN - 0022-5347
IS - 5
ER -